Published 2 years ago

Biogen CEO to Step Aside After Alzheimer’s Drug Struggles

Summary by Ground News

CEO Michel Vounatsos will continue to lead the Biogen until a successor is found. Aduhelm was the first new Alzheimer's drug introduction in nearly two decades. Initially priced at $56,000 a year, it was expected to quickly become a blockbuster drug that would generate billions for Biogen.

0 Articles

All

Left

Center

Right

Reuters

Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm

Biogen Inc said on Tuesday that chief executive Michel Vounatsos will step down and that the company is pulling back on selling its controversial Alzheimer's drug Aduhelm, in what appears to be a final blow to its prospect of becoming a big seller.

2 years ago·United Kingdom

Read Full Article

Associated Press News

Change at the top for Biogen after Alzheimer's drug flops

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer's drug Aduhelm less than a year after the medication's launch triggered a backlash from experts, doctors and insurers.

2 years ago·United States

Read Full Article

abc News

Change at the top for Biogen after Alzheimer's drug flops

Biogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled

2 years ago·United States

Read Full Article

Washington Times

Change at the top for Biogen after Alzheimer’s drug flops

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer’s drug Aduhelm less than a year after the medication’s launch triggered a backlash from experts, doctors and insurers.

2 years ago·United States

Read Full Article

KIFI

Change at the top for Biogen after Alzheimer's drug flops - Local News 8

MATTHEW PERRONE and TOM MURPHYBiogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled. The company said Tuesday that current CEO Michel Vounatsos will continue to lead the company until his successor is appointed. Aduhelm hit the market as the first new Alzheimer’s medication in nearly two decades. But although the company slashed the price in half, Aduhelm’s rollout has been disastrous. …

2 years ago·Idaho Falls, United States

Read Full Article

CNBC

Biogen CEO to step down as the drugmaker plans further Aduhelm cost cuts

Biogen's Chief Executive Officer Michel Vounatsos is stepping down as it is grappling with Medicare restricting coverage for its Alzheimer's drug Aduhelm.

2 years ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.